PO.BCS01.03 · 生物信息与计算
输卵管上皮体细胞突变的累积与克隆结构
Accumulation of somatic mutation and clonal architecture of fallopian tube epithelium
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:高级别浆液性卵巢癌(HGSOC)是上皮性卵巢癌最常见的亚型,其特征为体细胞TP53突变(≈96%)以及在15~20%病例中出现的种系或体细胞BRCA1/2突变。越来越多的证据表明,输卵管伞端而非卵巢,是大多数HGSOC的主要起源细胞。尽管有此证据,壶腹部与伞端上皮之间的直接基因组比较一直缺乏。虽然体细胞突变会逐渐累积,但由于重建克隆谱系的挑战,这些过程如何塑造正常输卵管上皮的克隆结构仍不甚明确。
方法:从手术切除的组织中衍生输卵管上皮类器官,并在3D matrigel中培养。我们从BRCA1/2种系突变携带者(BRCA1 n=3;BRCA2 n=1)和一名BRCA野生型个体中获取的解剖学上不同的输卵管上皮区域(壶腹部和伞端),建立了单细胞来源的克隆类器官。低输入DNA文库在Illumina NovaSeqX上进行测序(约15×),以识别体细胞单碱基替换(SBS)、小插入和缺失(indels)以及结构变异(SVs),随后进行突变特征提取和系统发育重建,以揭示克隆扩增动态。
结果:在所分析的五名患者中,体细胞突变负荷与年龄仅显示出微弱且统计学上不精确的相关性,点估计表明每年增加7.12个SBS(95% CI,-9.6至23.9)和0.04个indels(95% CI,-2.65至2.73)。壶腹部和伞端类器官之间的总SBS和indels负荷相当,且与种系BRCA1/2状态、产次或绝经年龄基本无关,尽管鉴于样本量有限,这些无关联结果应谨慎解读。两个区域均未检测到SVs。BRCA1/2种系携带者未表现出HRD相关特征,提示正常上皮中不存在体细胞水平的单倍剂量不足。系统发育分析识别出区域特异性的克隆动态:伞端类器官经常显示出在青春期或之后出现的晚期克隆扩增事件。在两个区域均检测到癌症相关变异(如TP53、MET、CSMD3),但仍需要更多克隆扩增的样本来评估区域特异性富集。
结论:体细胞突变随年龄在输卵管上皮中累积,但仅BRCA单倍剂量不足并不导致同源重组缺陷。伞端的区域特异性晚期克隆扩增,可能受其受限的指状结构影响,或许是HGSOC起源于该解剖部位的发病率不成比例地更高的原因。目前正在进行样本扩增,以完善演化模型。
查看英文原文 English abstract
Background: High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of epithelial ovarian cancer, characterized by somatic TP53 mutations (≈ 96 %) and by germline or somatic BRCA1 / 2 mutations in 15~20 % of cases. Mounting evidence suggests that the fallopian tube fimbria, rather than the ovary, serves as the predominant cell-of-origin for the majority of HGSOC. Despite this evidence, a direct genomic comparison between ampullary and fimbrial epithelia has been lacking. Although somatic mutations accumulate gradually, it remains poorly defined due to challenges in reconstructing clonal lineages how these processes shape clonal architecture in normal fallopian tube epithelium.
Methods: Fallopian tube epithelial organoids were derived from surgically resected tissues and cultured in 3D matrigel. We established single cell-derived clonal organoids from anatomically distinct fallopian tube epithelial regions (ampulla and fimbria) obtained from BRCA1/2 germline mutation carriers ( BRCA1 n=3; BRCA2 n=1) and one BRCA wild-type individual. Low-input DNA libraries were sequenced on the Illumina NovaSeqX (~15×) to identify somatic single-base substitutions (SBS), small insertions and deletions (indels), and structural variants (SVs), followed by mutational signature extraction and phylogenetic reconstruction to reveal clonal expansion dynamics.
Results: Across the five patients analyzed, somatic mutation burden showed only a weak and statistically imprecise correlation with age, with point estimates indicating annual increases of 7.12 SBS (95% CI, -9.6 to 23.9) and 0.04 indels (95% CI, -2.65 to 2.73). Total SBS and indels burdens were comparable between ampullary and fimbrial organoids and largely unrelated to germline BRCA1/2 status, parity, or menopausal age, although these null associations should be interpreted cautiously given the limited sample size. No SVs were detected in either region. BRCA1/2 germline carriers did not exhibit HRD-associated signatures, suggesting absence of somatic-level haploinsufficiency in normal epithelium. Phylogenetic analyses identified region-specific clonal dynamics: fimbrial organoids frequently showed late clonal expansion events emerging during adolescence or later. Cancer-related variants (e.g., TP53, MET, CSMD3 ) were detected in both regions, though additional clonally expanded samples will be required to evaluate region-specific enrichment.
Conclusions: Somatic mutations accumulate with age in the fallopian tube epithelium, but BRCA haploinsufficiency alone does not confer homologous recombination deficiency. Region-specific late clonal expansion in the fimbria, potentially influenced by its constrained, finger-like architecture, may underlie the disproportionately higher incidence of HGSOC originating from this anatomical site. Ongoing sample expansion is underway to refine evolutionary models.
利益披露 Disclosure
S. Kim, None..
W. Seo, None..
S. Kim, None..
T. Park, None..
M. Kim, None..
B. Keam, None..
T. Kim, None..
D. Kim, None..
S. Kim, None..
J. Youk, None.